CN113528650A - Tmp21基因的表达可以作为自闭症早期筛查、早期识别和症状严重程度预测的客观指标 - Google Patents
Tmp21基因的表达可以作为自闭症早期筛查、早期识别和症状严重程度预测的客观指标 Download PDFInfo
- Publication number
- CN113528650A CN113528650A CN202110884198.4A CN202110884198A CN113528650A CN 113528650 A CN113528650 A CN 113528650A CN 202110884198 A CN202110884198 A CN 202110884198A CN 113528650 A CN113528650 A CN 113528650A
- Authority
- CN
- China
- Prior art keywords
- tmp21
- expression
- autism
- gene
- nrf2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000831851 Homo sapiens Transmembrane emp24 domain-containing protein 10 Proteins 0.000 title claims abstract description 78
- 230000014509 gene expression Effects 0.000 title claims abstract description 76
- 206010003805 Autism Diseases 0.000 title claims abstract description 52
- 208000020706 Autistic disease Diseases 0.000 title claims abstract description 52
- 238000012216 screening Methods 0.000 title claims description 6
- 208000024891 symptom Diseases 0.000 title abstract description 22
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 claims abstract description 119
- 102100024180 Transmembrane emp24 domain-containing protein 10 Human genes 0.000 claims abstract description 62
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 claims abstract description 57
- 229960005559 sulforaphane Drugs 0.000 claims abstract description 57
- 235000015487 sulforaphane Nutrition 0.000 claims abstract description 57
- 239000003814 drug Substances 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 37
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 238000010172 mouse model Methods 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 238000002651 drug therapy Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 8
- 108700008625 Reporter Genes Proteins 0.000 abstract 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 63
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 62
- 230000008859 change Effects 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 16
- 239000000902 placebo Substances 0.000 description 15
- 229940068196 placebo Drugs 0.000 description 15
- 208000029560 autism spectrum disease Diseases 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 12
- 238000012163 sequencing technique Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000030279 gene silencing Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 230000006399 behavior Effects 0.000 description 6
- 239000007850 fluorescent dye Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000011813 knockout mouse model Methods 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 230000003321 amplification Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 206010042008 Stereotypy Diseases 0.000 description 3
- 208000013404 behavioral symptom Diseases 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000012226 gene silencing method Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 231100000867 compulsive behavior Toxicity 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001521 two-tailed test Methods 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101100369960 Mus musculus Tmed10 gene Proteins 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 208000012202 Pervasive developmental disease Diseases 0.000 description 1
- 208000033712 Self injurious behaviour Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Environmental Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
本发明公开了一种与孤独症病程相关的报告基因TMP21，孤独症患者体内TMP21低表达，通过给药萝卜硫素(Sulforaphane,SFN)，能够有效缓解孤独症症状，并且提高TMP21表达量，从而为孤独症严重程度和用药治疗提供了客观指标。
Description
技术领域
本发明涉及疾病诊断和治疗领域，具体的说，涉及孤独症谱系障碍病程相关核酸表达的诊断和药物治疗。
背景技术
孤独症谱系障碍(Autism Spectrum Disorder,ASD)是一种高发病率的广泛性儿童神经发育障碍性疾病。这类障碍主要包括狭义自闭症、亚斯伯格症、儿童崩解症、广泛性发育障碍等一系列症状共通而程度不一的疾病。世界卫生组织最新报告显示全球ASD平均患病率约为62/10000(0.62％)，我国ASD患病率约为1％，男性大于女性，农村大于城市，且每年持续上升。
尽管进行了大量的研究工作，但是目前ASD的病因和发病机制尚未完全明确，普遍认为涉及遗传和环境因素之间复杂的相互作用。ASD病因的复杂性和临床表现的异质性限制了有效的治疗药物和干预措施的发展。美国食品和药物管理局(FDA)批准了两种非典型抗精神病药物用于临床ASD患者治疗。但药物无法改变ASD基本病程，仅限于控制某些行为症状，如刻板或强迫性行为、多动或冲动性行为、攻击或自伤性行为等，对于ASD核心症状作用较小。
虽然没有单一的药物或干预措施能够全面改善ASD的行为症状，但相关研究仍在不断取得进展。目前治疗体系倾向于根据患儿不同年龄和症状特点，采取灵活多样的综合干预措施，以行为干预为主，药物治疗为辅。全球已有多家临床机构已经完成或正在开展萝卜硫素(Sulforaphane,SFN)对自闭症治疗效果的临床试验。
早期识别早期干预是提高自闭症治疗有效性的重要环节，然而，目前尚无可靠的客观指标能早期识别自闭症患者。另一方面，SFN对自闭症治疗的有效性也存在极大的个体差异，目前尚不清楚SFN治疗自闭症有效性的生物学机制。目前亟待寻找与疾病症状严重程度相关的客观指标，一方面有助于早期识别自闭症患者，预测其症状严重程度；另一方面为有效治疗自闭症提供新的靶点。
发明内容
本发明针对自闭症症状严重程度相关的客观指标，提供了一种与自闭症病症状病程相关的基因TMP21，设计了其扩增引物，通过检测TMP21基因的表达水平，监测自闭症症状严重程度和病情改善程度，且进一步阐明了SFN通过TMP21改善自闭症症状可能的机制，提示TMP21基因的表达可以作为自闭症早期识别和症状严重程度预测的客观指标。
具体的，本发明提供了以下技术方案：
第一方面，本发明对SFN治疗自闭症的效果进行了验证，针对自闭症患者进行药物治疗和对照实验；其中，所述药物是SFN，对照组为服用安慰剂(Placebo,PLA)，根据自闭症症状改善程度，对施用药物进行分组，判断SFN药物的有效程度。
使用医生评定量表来评估患者治疗前后的临床症状变化。医生评定量表《OSU孤独症评定量表—DSM-IV》(OSU Autism Rating Scale-DSM-IV,OARS-4)(OSU总分平均分是社交障碍、沟通障碍和重复刻板行为评定的三者平均分)，此量表不仅有总分可以评估被试相应问题的总体严重程度，而且都包含丰富维度，适合应用于临床表型与生物特征的关联研究。我们发现OSU总分平均分在治疗前后有改变的趋势但无显著差异。经过分组后，根据施用药物对比，发现SFN对自闭症的治疗具有个体差异。
进一步的，所述治疗药物可以是其他控制某些行为症状，如刻板或强迫性行为、多动或冲动性行为、攻击或自伤性行为的药物，例如利培酮和阿立哌唑等。
第二方面，本发明提供了一种基因TMP21作为自闭症患者症状严重程度和改善程度的客观指标TMP21，所述TMP21基因的GenBank登录号为：NM_006827。
通过抽取自闭症患者和正常人外周血，提取mRNA，进行转录组测序。同时患者在治疗前后，根据OSU平均分改变程度，将患者改善程度不同分为四组：萝卜硫素组OSU改变程度大、萝卜硫素组OSU改变程度小、安慰剂组OSU改变程度大、安慰剂组OSU改变程度小，并进行转录组数据分析。在三百多差异表达的基因中，我们筛选出一个重要的差异基因，即TMP21的表达在患者中较正常对照组显著下降，经过SFN治疗之后TMP21的表达有明显上升，尤其是在治疗有效组中的TMP21表达显著上升(p＝0.0513)。
转录组测序分析统计方法如下所示：使用非配对的t检验进行两组间的比较，定义置信区间为95％，双尾检验。P<0.05认为具有显著性差异(*)，P<0.01认为差异很显著(**)，P<0.001认为差异极其显著(***)。
进一步公开了检测TMP21基因表达水平的引物以及抗体；利用所述引物进行转录组检测，以及利用所述抗体进行特异性结合。分析发现OSU的改变程度和TMP21表达的变化程度成负相关，这些结果提示SFN显著改善自闭症症状的机制可能是由于改变TMP21的表达所引起的，TMP21的表达与自闭症症状的改善程度显著相关。
第三方面，本发明公开了SFN改变TMP21表达水平的作用机制。
通过基因工程手段构建Nrf2基因沉默和过表达细胞模型，采用相同培养条件培养，添加SFN后，定时检测TMP21以及Nrf2的表达情况，并设置内参。同时构建荧光蛋白标记，共聚焦显微镜下观察TMP21以及Nrf2表达变化。
结果显示，SFN能够激活细胞中Nrf2表达进而调控TMP21的表达。
优选地，在添加SFN后，沉默Nrf2或者高表达Nrf2开始计时，分别在不同时间段取样，提取细胞总蛋白和总mRNA，对总蛋白使用前述抗体进行蛋白电泳，对Nrf2 mRNA和TMP21mRNA反转录并使用前述引物进行扩增。并且将表达量明显区别于对照组的基因作为待选基因。
优选地，所述取样时间为0h、24h、48h。
优选地，所述检测蛋白和基因表达使用的方法为：Western blot，qPCR以及其蛋白荧光标记等手段。
优选地，根据上述细胞模型，使用的是神经细胞系SH-SY5Y。
优选地，上述基因工程手段构建的Nrf2基因沉默细胞模型可以是瞬时沉默，沉默组为将靶向Nrf2的siRNA转染至上述细胞(Nrf2-siRNA)，对照组为转染空白质粒(Ctr-siRNA)。
优选地，上述基因工程操作中，过表达Nrf2细胞模型中，过表达组转染使用高表达质粒pCDNA4-Nrf2，对照组转染使用pcDNA4空白质粒。
优选地，检测TMP21以及Nrf2两种蛋白表达水平可以使用分别针对Nrf2和TMP21的单克隆或多克隆抗体。
优选地，所述蛋白荧光标记可以是红色荧光标签和绿色荧光标签，也可以是其他不同颜色的蛋白荧光标记。
优选地，所述SFN改变TMP21表达水平的作用机制是通过调节Nrf2的表达，进而调控TMP21基因的表达。
第四方面，Nrf2调控TMP21基因表达的动物模型验证。
所述验证是通过下述方法实现的：
构建Nrf2基因敲除小鼠模型(Nrf2 KO)，并以野生型(WT)作为对照，从小鼠出生开始计时，分别在不同时间分离小鼠脑海马组织，提取海马组织总蛋白和总mRNA，对总蛋白进行蛋白电泳后使用前述抗体结合，对TMP21 mRNA反转录并使用前述引物进行扩增，检测不同日龄的小鼠体内TMP21和Nrf2含量变化。
优选的，WT和Nrf2基因敲除小鼠(Nrf2 KO)来源于赛业生物Nrf2基因敲除杂合子小鼠(Nrf2+/-)相互繁殖的后代。Nrf2基因敲除杂合子小鼠品系名称为C57BL/6-Nfe212tm1cyagen，品系编号为KOCMP-21018-Nfe212。
优选地，所述取样时间为4天，15天，35天，75天，120天，180天。
优选地，动物体内研究表明，Nrf2和TMP21的表达具有正相关性，Nrf2调控TMP21的表达。
第五方面，本申请公开的TMP21基因作为自闭症的客观指标，用来作为筛选药物以及诊断用途，可以极大的丰富治疗自闭症的药物的可选择性以及提高自闭症的确诊率。
进一步的，将所述基因表达的产品制备成改善自闭症的药物。
过表达或敲低TMP21基因的表达在构建小鼠模型以及模型筛选药物中的应用。
本发明的有益效果包括：
1.本发明首次证实了TMP21在ASD患者中表达量显著下降，而经过SFN治疗后，TMP21的表达增加，尤其是治疗有效的患者，TMP21的表达是显著上升的。
2.本发明首次公开了SFN通过影响TMP21的表达从而改善自闭症症状的机制，即通过促进Nrf2的表达增加TMP21的表达，表达TMP21是自闭症治疗的一个新靶点，为自闭症病程改变提供了参考依据。
附图说明
为了更清楚的说明本申请实施例中的技术方案，下面将对实施例中所需要使用的附图做简单的介绍，显而易见的下面描述中的附图，仅仅是本申请中记载的一些实施例，对于本领域普通技术人员来说，在不付出创造性劳动的前提下，还可以根据这些附图获得其他的技术方案以及相应的附图。
图1 SFN和安慰剂治疗自闭症效果图，其中，(A)SFN治疗组和安慰剂组OSU评分，(B)SFN和安慰剂组不同改变程度比较。
图2自闭症病程相关基因筛选图，其中，(A)TMP21在自闭症和正常人外周血中表达量差异，(B)SFN和安慰剂治疗自闭症过程中TMP21表达量变化，(C)SFN和安慰剂组不同改变程度中TMP21表达量分析。
图3 SFN组不同改变程度对TMP21 mRNA表达量变化影响。
图4 OSU评分和TMP21表达量关系。
图5 SFN对Nrf2和TMP21表达量变化的影响，其中，(A)为Western blot检测在SH-SY5Y细胞经过溶媒对照、SFN处理24h和48h后Nrf2和TMP21的蛋白表达；B为qPCR检测对照组、SFN处理24h和SFN处理48h后Nrf2和TMP21的mRNA表达；(C)为过表达Nrf2、沉默Nrf2以及添加SFN对TMP21表达量的影响；(D)为SH-SY5Y细胞经过溶媒对照、SFN处理24h和48h后，Nrf2和TMP21蛋白表达量荧光标记，Nrf2：绿色荧光标记、TMP21：红色荧光标记。
图6 Nrf2敲除小鼠模型和野生型小鼠中TMP21和Nrf2表达量变化，其中(A)为Nrf2沉默小鼠和野生型小鼠不同时间段TMP21和Nrf2蛋白表达量变化；(B)Nrf2沉默小鼠和野生型小鼠不同时间段TMP21mRNA含量变化。
具体实施方式
实施例1：SFN治疗自闭症效果检测
收集24例患者以及21例性别年龄匹配的正常对照作为研究对象，其中12个患者服用SFN，12个患者服用安慰。使用医生评定量表来评估患者治疗前后的临床症状变化。医生评定量表《OSU孤独症评定量表—DSM-IV》(OSU Autism Rating Scale-DSM-IV，OARS-4)(OSU总分平均分是社交障碍、沟通障碍和重复刻板行为评定的三者平均分)，此量表不仅有总分可以评估被试相应问题的总体严重程度，而且都包含丰富维度，适合应用于临床表型与生物特征的关联研究。
实验结果如图1所示，我们发现OSU总分平均分在治疗前后有改变的趋势但无显著差异(图1A)。
为了更好的确定SFN治疗自闭症的有效性，根据OSU平均分改变程度，我们将24例病患分成四组，所述分组如下：
萝卜硫素组OSU改变程度大(SFN OSU L)；
萝卜硫素组OSU改变程度小(SFN OSU S)；
安慰剂组OSU改变程度大(PLA OSU L)；
安慰剂组OSU改变程度小(PLA OSU S)。
每组各6人，然后进行数据分析，结果如图1B所示：其中SFN OSU L分析显示OSU组前后比较有显著差异，说明SFN OSU L组对SFN治疗最有效。而根据SFN OSU S和SFN OSU L组以及安慰剂组中OSU评分比较，揭示了SFN对自闭症的治疗具有个体差异。
实施例2：自闭症病程相关基因的筛选
21例正常对照及24例患者在治疗前后分别进行外周血采集，采用标准抽提方法从外周全血中提取mRNA，利用真核生物大部分mRNA都带有polyA尾的结构特征，通过Oligo(dT)磁珠富集带有polyA尾的mRNA，通过RNA纯度及完整性质控检测之后，进行转录组测序。转录组测序的基本原理是边合成边测序(Sequencing by Synthesis)。在测序的flow cell中加入四种荧光标记的dNTP、DNA聚合酶以及接头引物进行扩增，在每一个测序簇延伸互补链时，每加入一个被荧光标记的dNTP就能释放出相对应的荧光，测序仪通过捕获荧光信号，并通过计算机软件将光信号转化为测序峰，从而获得待测片段的序列信息。进一步通过与基因组数据库比对，对数据进行基因注释，同时考虑测序深度和基因长度对读数计数的影响，计算映射到每个基因的读数，即基因的表达水平。我们先比较21例正常对照及24例患者在治疗前后的全基因组表达水平，然后进一步根据OSU平均分改变程度，我们将其分成四组，具体分组如实施例1所示，并对所述四组分组进行转录组数据分析。
上述测序使用的引物序列如下所示：
人TMP检测引物：
hTMP E4 F：CCATTAGAGGTAGAGCTGCG
hTMP E5 R：ACTCAATCAATTTCTTGGCC。
转录组测序分析统计方法如下所示：使用非配对的t检验进行两组间的比较，定义置信区间为95％，双尾检验。P<0.05认为具有显著性差异(*)，P<0.01认为差异很显著(**)，P<0.001认为差异极其显著(***)。
在三百多差异表达的基因中，我们筛选出一个重要的差异基因，即TMP21的表达在患者中较正常对照组显著下降(图2A)，经过SFN治疗之后TMP21的表达有明显上升(图2B)，尤其是在治疗有效组中的TMP21表达显著上升(p＝0.0513)(图2C、图3)。由此，可以认为OSU的改变程度和TMP21表达的变化程度成负相关(图4)，这些结果提示SFN显著改善自闭症症状的机制可能是由于改变TMP21的表达所引起的，TMP21的表达与自闭症症状的改善程度显著相关。
实施例3：SFN通过激活Nrf2提高TMP21表达量。
为确定添加SFN是如何引起TMP21表达量变化，筛选了备选基因进行细胞模型验证，具体步骤如下：
1)、使用神经细胞系SH-SY5Y作为实验对象，分别制备Nrf2沉默和高表达细胞模型，并使用空白质粒作为对照；
其中，Nrf2基因沉默细胞模型是通过siRNA技术实现，将携带有靶向Nrf2的siRNA的质粒转染至上述细胞(Nrf2-siRNA)，对照组为转染空白质粒(Ctr-siRNA)。同样的，过表达细胞模型使用高表达质粒pCDNA4-Nrf2转染至细胞，对照组转染使用pcDNA4空白质粒，并设置不加SFN的阴性对照组。
2)、构建模型后24h添加SFN，并在第48h取样，细胞破碎后，提取总蛋白和总mRNA进行蛋白电泳和qPCR分析，并设置内参。检测方法如下：蛋白检测为方法为Western blot，分别使用特异性结合Nrf2和TMP21的单克隆抗体或多克隆抗体进行蛋白印染验证，qPCR检测方法为使用前述引物组扩增测序。
3)、分别使用红色荧光标签和绿色荧光标签对TMP21何Nrf2进行标记，并且添加SFN，后续定期通过共聚焦显微镜观察两种蛋白荧光强度。
结果如下：空白对照组中，SFN作用于神经细胞系SH-SY5Y能显著增加Nrf2的表达的同时显著增加TMP21的表达(图5A-B)，并且随着SFN加药时间推移，Nrf2和TMP21表达量呈现出先升高后降低的趋势。
进一步确定SFN通过激活Nrf2提高TMP21的表达，可以看出，SFN或高表达Nrf2均可上调TMP21的蛋白表达，而沉默Nrf2基因后SFN促进TMP21表达的作用效果降低(图5C)。在共聚焦显微镜下拍摄的Nrf2和TMP21的荧光信号(图5D)，与图5A-C结果一致。
实施例4.Nrf2对TMP21表达量影响动物模型实验。
为更加准确的确定Nrf2与TMP21之间的相互作用关系，构建WT小鼠和Nrf2 KO小鼠模型，进行动物水平实验验证，具体步骤如下：
构建Nrf2基因敲除小鼠模型(Nrf2 KO)，并以野生型(WT)作为对照，WT和Nrf2基因敲除小鼠(Nrf2 KO)来源于赛业生物Nrf2基因敲除杂合子小鼠(Nrf2+/-)相互繁殖的后代。Nrf2基因敲除杂合子小鼠品系名称为C57BL/6-Nfe212tm1cyagen，品系编号为KOCMP-21018-Nfe212。从小鼠出生开始计时，分别在小鼠出生的第4天，15天，35天，75天，120天，180天分离小鼠脑海马组织，提取海马组织总蛋白和总mRNA，对总蛋白使用前述抗体进行蛋白电泳，对TMP21 mRNA反转录并使用前述引物进行扩增，检测不同日龄的小鼠体内TMP21和Nrf2含量变化，具体操作步骤如前所述。
其中，小鼠TMP21 qPCR引物序列如下所示：
qP mTMP F:TTGAGAGCAAGGGAACAGGG
qP mTMP R:CGTCGTAACTCCACCTCCAG。
结果显示：Nrf2和TMP21蛋白的表达均随年龄增加呈现出先增后减的趋势，在Nrf2KO小鼠中，TMP21蛋白的表达显著下降(图6)。结合之前临床试验结果，提示SFN是通过Nrf2增加TMP21蛋白的表达，从而达到改善自闭症症状的作用。
Claims (9)
1.检测TMP21基因表达的试剂在制备检测药物治疗孤独症进程的试剂盒或药物中的应用。
2.检测TMP21基因表达的试剂在制备指导药物治疗孤独症进程的试剂盒或药物中的应用。
3.根据权利要求1或2所述应用，其特征在于，所述TMP21基因的GenBank登录号为：NM_006827。
4.根据权利要求1或2所述的应用，其特征在于，所述检测TMP21基因表达的试剂包括针对TMP21的引物、抗体。
5.根据权利要求1或2所述应用，其特征在于，所述药物为萝卜硫素(Sulforaphane，SFN)。
6.敲低TMP21基因表达的载体在制备孤独症小鼠模型中的应用。
7.权利要求1中所述的检测TMP21基因表达的试剂在筛选治疗孤独症药物中的应用，所述试剂包括针对TMP21的抗体、引物。
8.过表达权利要求1所述的检测TMP21基因的核酸构建体在制备治疗或辅助治疗孤独症药物中的应用。
9.权利要求1所述TMP21基因表达的蛋白在制备治疗孤独症药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110884198.4A CN113528650B (zh) | 2021-08-03 | 2021-08-03 | Tmp21基因的表达可以作为自闭症早期筛查、早期识别和症状严重程度预测的客观指标 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110884198.4A CN113528650B (zh) | 2021-08-03 | 2021-08-03 | Tmp21基因的表达可以作为自闭症早期筛查、早期识别和症状严重程度预测的客观指标 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113528650A true CN113528650A (zh) | 2021-10-22 |
| CN113528650B CN113528650B (zh) | 2022-03-08 |
Family
ID=78090228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110884198.4A Active CN113528650B (zh) | 2021-08-03 | 2021-08-03 | Tmp21基因的表达可以作为自闭症早期筛查、早期识别和症状严重程度预测的客观指标 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113528650B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114141374A (zh) * | 2021-12-07 | 2022-03-04 | 中南大学湘雅二医院 | 孤独症发病预测模型构建方法、预测方法及装置 |
| CN114622026A (zh) * | 2022-04-02 | 2022-06-14 | 中南大学湘雅二医院 | 拟杆菌作为预测自闭症疗效的客观指标 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070669A2 (en) * | 2001-03-06 | 2002-09-12 | Incyte Genomics, Inc. | Secreted proteins |
| US20090203014A1 (en) * | 2008-01-02 | 2009-08-13 | Children's Medical Center Corporation | Method for diagnosing autism spectrum disorder |
| CN109821019A (zh) * | 2017-11-06 | 2019-05-31 | 斯塔利克拉股份有限公司 | 用于治疗自闭症的药物组合物 |
| CN110679548A (zh) * | 2019-10-24 | 2020-01-14 | 南方医科大学南方医院 | 一种自闭症小鼠模型的构建方法 |
| CN110946996A (zh) * | 2019-05-08 | 2020-04-03 | 深圳福山生物科技有限公司 | 包含萝卜硫苷的组合物及其用途 |
| US20200157628A1 (en) * | 2007-10-04 | 2020-05-21 | The Hospital For Sick Children | Biomarkers for Autism Spectrum Disorders |
| CN111511407A (zh) * | 2017-11-06 | 2020-08-07 | 斯大利卡拉公司 | Asd亚型的治疗 |
| CN111910000A (zh) * | 2020-07-02 | 2020-11-10 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种预测鼻咽癌预后的肿瘤微环境成分标志物组合及系统 |
-
2021
- 2021-08-03 CN CN202110884198.4A patent/CN113528650B/zh active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070669A2 (en) * | 2001-03-06 | 2002-09-12 | Incyte Genomics, Inc. | Secreted proteins |
| US20200157628A1 (en) * | 2007-10-04 | 2020-05-21 | The Hospital For Sick Children | Biomarkers for Autism Spectrum Disorders |
| US20090203014A1 (en) * | 2008-01-02 | 2009-08-13 | Children's Medical Center Corporation | Method for diagnosing autism spectrum disorder |
| CN109821019A (zh) * | 2017-11-06 | 2019-05-31 | 斯塔利克拉股份有限公司 | 用于治疗自闭症的药物组合物 |
| CN111511407A (zh) * | 2017-11-06 | 2020-08-07 | 斯大利卡拉公司 | Asd亚型的治疗 |
| CN111511406A (zh) * | 2017-11-06 | 2020-08-07 | 斯大利卡拉公司 | 用于诊断自闭症谱系疾病亚型的挑战试验 |
| CN110946996A (zh) * | 2019-05-08 | 2020-04-03 | 深圳福山生物科技有限公司 | 包含萝卜硫苷的组合物及其用途 |
| CN110679548A (zh) * | 2019-10-24 | 2020-01-14 | 南方医科大学南方医院 | 一种自闭症小鼠模型的构建方法 |
| CN111910000A (zh) * | 2020-07-02 | 2020-11-10 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种预测鼻咽癌预后的肿瘤微环境成分标志物组合及系统 |
Non-Patent Citations (7)
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114141374A (zh) * | 2021-12-07 | 2022-03-04 | 中南大学湘雅二医院 | 孤独症发病预测模型构建方法、预测方法及装置 |
| CN114622026A (zh) * | 2022-04-02 | 2022-06-14 | 中南大学湘雅二医院 | 拟杆菌作为预测自闭症疗效的客观指标 |
| CN114622026B (zh) * | 2022-04-02 | 2024-10-01 | 中南大学湘雅三医院 | 拟杆菌作为预测自闭症疗效的客观指标 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113528650B (zh) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sun et al. | Preliminary comparison of plasma notch-associated microRNA-34b and-34c levels in drug naive, first episode depressed patients and healthy controls | |
| Ceylan et al. | Circulating exosomal microRNAs in bipolar disorder | |
| Matamala et al. | Genome-wide circulating microRNA expression profiling reveals potential biomarkers for amyotrophic lateral sclerosis | |
| CN113528650B (zh) | Tmp21基因的表达可以作为自闭症早期筛查、早期识别和症状严重程度预测的客观指标 | |
| Lopez et al. | Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes | |
| US12006551B1 (en) | MiRNA marker for diagnosis and/or treatment of alzheimer's disease | |
| KR20180039631A (ko) | 염색체 상호작용 부위를 이용하는 검출 방법 | |
| CN110151742B (zh) | 大麦芽碱在制备治疗垂体瘤药物中的用途 | |
| Levine et al. | Transcriptome analysis of HIV-infected peripheral blood monocytes: gene transcripts and networks associated with neurocognitive functioning | |
| CN106434982A (zh) | 缺血性脑卒中相关的分子标记物及其应用 | |
| CN110295225A (zh) | 用于指导洛伐他汀药物个体化用药相关基因检测的引物组合及试剂盒及方法 | |
| CN113005142A (zh) | doc2α和doc2β基因缺失斑马鱼突变体的制备及斑马鱼自闭症模型的构建方法 | |
| CN110387415A (zh) | 一种检测脑缺血再灌注损伤的环状rna标志物及应用 | |
| AU2020103707A4 (en) | miRNA MARKER FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE | |
| Fang et al. | Histological, functional and transcriptomic alterations in the juvenile hippocampus in a mouse model of thyroid hormone resistance | |
| CN111549117B (zh) | 一种生物标志物及其在帕金森中应用 | |
| CN116425854B (zh) | 焦虑及抑郁相关疾病的生物标记物及试剂盒和药物 | |
| Wu | A MENDELIAN RANDOMIZATION STUDY SUPPORTS CAUSAL EFFECT OF OVERWEIGHT ON LONGEVITY | |
| CN116763809B (zh) | miR-376b-3p的抑制物在制备治疗癫痫药物中的应用 | |
| CN103272248A (zh) | miR-15b在制备糖尿病诊疗制剂中的应用 | |
| CN111733260B (zh) | 一种与高原低氧耐受适应性相关的多态性位点及其应用 | |
| CN113151445B (zh) | 一种智力障碍疾病相关的atrx基因的突变位点及检测试剂盒 | |
| CN117007816B (zh) | 靶点Nesfatin-1在预防或治疗血管钙化中的应用 | |
| Hamilton et al. | 2022-2023 SSGSA STEM Sustainability Case Competition: Genetic Engineering | |
| CN117587120A (zh) | miR-20a-5p在制备抑郁症的诊断或预后评估的分析试剂或试剂盒中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230327 Address after: Room 2404, Building 4, Lujiang Spring, No. 89, Yuelu Avenue, Yuelu District, Changsha City, Hunan Province, 410006 Patentee after: Zhang Xiaojie Address before: 410011 No. 89, Yuelu Avenue, Yuelu District, Changsha City, Hunan Province Patentee before: Changsha aikeman Biotechnology Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240512 Address after: No. 410011, Furong Middle Road, Changsha City, Hunan Province Patentee after: THE SECOND XIANGYA HOSPITAL OF CENTRAL SOUTH University Country or region after: China Address before: Room 2404, Building 4, Lujiang Spring, No. 89, Yuelu Avenue, Yuelu District, Changsha City, Hunan Province, 410006 Patentee before: Zhang Xiaojie Country or region before: China |